[144] DexCom, Inc. SEC Filing
Rhea-AI Filing Summary
Form 144 notice for proposed sale of securities under Rule 144. The filing shows an intended sale of 500 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $40,145, slated for 08/15/2025 on NASDAQ. The shares were acquired as restricted stock on 03/08/2024 from the issuer and paid in full on that date. The filing also reports three sales by the same person in the past three months totaling 11,000 shares for gross proceeds of $920,264. The filing identifies the seller in prior sales as Michael Brown.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine Rule 144 notice for a small planned sale; disclosure aligns with required reporting of recent disposals.
The filing documents a proposed small-volume sale of restricted shares via a broker and lists recent dispositions in the prior three months. Key compliance points are present: acquisition date, nature of acquisition, broker details, planned sale date and recent sales history. The absence of the issuer name in the issuer section is notable in this document but the metadata supplies the ticker. The transaction size is immaterial relative to the reported outstanding shares, indicating a low market impact.
TL;DR: Economically immaterial sale relative to company float; provides transparency on insider liquidity.
From a market perspective, the planned sale of 500 shares ($40k) and recent sales totaling 11,000 shares ($920k) are small versus 392,155,265 shares outstanding reported in the form, so these transactions are unlikely to affect pricing. The record shows restricted stock granted 03/08/2024 and subsequent periodic sales, which may reflect routine vesting and disposal. No material corporate events or large block trades are disclosed.